Current Status of Adverse Event Profile of Cyclosporine in Kidney, Stem Cell, and Heart Transplantations Using the Japanese Pharmacovigilance Database

Iku Niinomi, Saki Oyama, Ayaka Inada, Tomohito Wakabayashi, Tatsuya lida, Hiroko Kambara, Mayako Uchida, Yukako Sano, Keiko Hosohata

1. Education and Research Center for Clinical Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, JPN
2. Education and Research Center for Pharmacy Practice, Doshisha Women’s College of Liberal Arts, Kyotanabe-shi, JPN

Corresponding author: Keiko Hosohata, hosohata@gly.oups.ac.jp

Abstract

Background: Cyclosporine is widely used to prevent allograft rejection after transplantation. The purpose of this study was to clarify the adverse events profiles associated with cyclosporine in transplant patients using a spontaneous reporting system database.

Methods: Retrospective pharmacovigilance disproportionality analysis was conducted using the Japanese Adverse Drug Event Report (JADER) database, with the reporting odds ratio (ROR) and 95% confidence interval (CI) for each adverse event.

Results: The database comprised 3,327, 958, and 956 reports associated with cyclosporine in the kidney, stem cell, and heart transplant patients, respectively. Infectious and renal disorders were commonly detected in these transplant patients. The signal scores of cyclosporine for toxic nephropathy were noteworthy in the kidney (ROR: 15.1, 95% CI: 11-20.8) and stem cell (ROR: 216; 95% CI, 29.3-1593) transplantation. Cyclosporine in heart transplantation was strongly associated with gastric cancer (ROR, 39.4; 95% CI, 16.7-93.2), but not kidney or stem cell transplantation.

Conclusion: It was suggested that there is a diversity in the strength of the association between cyclosporine and adverse events in the kidney, stem cell, and heart transplantation. Our results may provide useful information for treatment with cyclosporine, although further research with more data is needed.

Categories: Transplantation, Public Health, Therapeutics
Keywords: japanese adverse drug event report (jader) database, reporting odds ratio (ror), spontaneous reporting system, transplantation, cyclosporine

Introduction

Calcineurin inhibitors, immunosuppressive agents, have been used for decades in solid organ transplantation to prevent rejection with improvement in long-term survival [1]. Cyclosporine has a similar mechanism of effect to tacrolimus, but experience with cyclosporine is much more extensive than that with tacrolimus. Cyclosporine as well as tacrolimus are narrow therapeutic index medications, which exhibit marked inter- and intra-patient variabilities on systemic exposure [2]. Therapeutic drug monitoring of cyclosporine in transplant patients has markedly evolved in routine clinical practice for individualized medicine.

Cyclosporine causes a large spectrum of adverse effects, and several adverse events have been reported, such as nephrotoxicity, arterial hypertension, neurotoxicity, increased rate of infections, diabetes, and cardiomyopathy [3, 4]. However, there is little information about adverse events that are most frequently responsible for cyclosporine used in all kinds of transplantation in a real-world setting.

Recently, spontaneous reporting systems have been utilized as a useful method of post-marketing drug safety surveillance for the detection of new adverse drug events or changes in the occurrence of adverse events, referred to as signal detection [5, 6]. The Japanese Adverse Drug Event Report (JADER) database is a largely published database for pharmacovigilance [7-10]. The objective of this study was to clarify the profile of adverse events by cyclosporine used in a variety of transplant patients using the JADER database.

Materials And Methods

The JADER dataset is publicly available and can be downloaded from the website of the Pharmaceuticals and Medical Devices Agency (PMDA) (www.pmda.go.jp). We used the dataset to which adverse event reports were submitted between April 2004 and January 2017. The JADER consists of the following types of data:

- Reports of adverse events
- Reports of concomitant use of drugs
- Reports of patient characteristics

How to cite this article

Niinomi I, Oyama S, Inada A, et al. (September 20, 2022) Current Status of Adverse Event Profile of Cyclosporine in Kidney, Stem Cell, and Heart Transplantations Using the Japanese Pharmacovigilance Database. Cureus 14(9): e29383. DOI 10.7759/cureus.29383
patient demographic information (DEMO), drug information (DRUG), adverse events (REAC), and medical history. The DEMO table was then linked to the DRUG and REAC tables using the ID number, as reported previously [7,9,11]. The contribution of the medication to adverse events was classified into three categories: "suspected medicine," "concomitant medicine," and "interaction." A "suspected medicine" is defined as a pharmaceutical product suspected of causing an adverse event. When the reporter suspects an interaction, he/she reports it as an "interaction." A "concomitant medicine" is defined as another pharmaceutical product used at the time of the adverse reaction. In signal detection analysis, a masking effect is defined as a condition whereby a given drug-event pair might be hidden by the presence of another product [12]. Then, we only extracted cases that were classified as "suspected medicine."

The adverse events and indications in the JADER database are coded as Preferred Terms (PTs), each of which is a single medical concept for a symptom, sign, disease diagnosis, therapeutic indication, or investigation, using the Medical Dictionary for Regulatory Activities (MedDRA). We compiled a cross-tabulation table based on two classifications: the presence or absence of the adverse event, and the suspected medicine. Then, we calculated the reporting odds ratio (ROR) by the following formula (Figure 1).

\[
\text{ROR} = \frac{a/b}{c/d}, \quad 95\% \text{ CI} = \exp \left\{ \log (\text{ROR}) \pm 1.96 \sqrt{\frac{1}{a} + \frac{1}{b} + \frac{1}{c} + \frac{1}{d}} \right\}
\]

FIGURE 1: ROR is calculated by the formula

where \(a\) - the number of patients with a target event when they received a target drug, \(b\) - the number of patients with non-target adverse events when they received a target drug, \(c\) - the number of patients with the target event when they received non-target drugs, \(d\) - the number of patients with non-target adverse events when they received non-target drugs.

Generally, ROR is used with the spontaneous reporting database as an index of the relative risk of drug-associated adverse events. A signal was considered to be present when the lower limit of the 95% confidence intervals (CI) of the ROR was > 1.

In this database, age, height, and weight information are indicated as follows: age in decades, height in centimetres, and weight in kilograms. These data are not given as continuous variables because of privacy considerations, so we could not conduct multiple analyses using them. All analyses were conducted using JMP Pro 12 (SAS Institute Inc., Cary, NC, USA).

**Results**

The database comprised 20,408 adverse event reports associated with cyclosporine. Of 20,408, 3,327 (16.3%), 1,499 (7.3%), 1,102 (5.4%), 958 (4.7%), and 956 (4.7%) reports involved kidney transplantation, nephrotic syndrome, aplastic anemia, stem cell transplantation, and heart transplantation, respectively (Table 1).

|               | N (%) |
|---------------|-------|
| Renal transplant | 3,327 (16.3) |
| Nephrotic syndrome | 1,499 (7.3) |
| Aplastic anemia | 1,102 (5.4) |
| Stem cell transplant | 958 (4.7) |
| Heart transplant | 956 (4.7) |
| Psoriasis | 930 (4.6) |
| Prophylaxis against transplant rejection | 921 (4.5) |
| Unknown/Others | 10,715 (52.5) |

**TABLE 1: Most frequent reasons for use of cyclosporine**

To gain insight into how cyclosporine is associated with adverse events under its use for the prevention of
rejection after transplantation, we focused on kidney, stem cell, and heart transplantations for further analysis. As shown in Table 2, approximately 60%, 50%, and 90% of patients were male in the kidney, stem cell, and heart transplant patients with adverse events receiving cyclosporine, respectively. According to the age distribution of these transplant patients, adverse events associated with cyclosporine occurred frequently in kidney transplant patients in their 50s, stem cell transplant patients in their 50s, and heart transplant patients in their 10s, respectively. The mean dose of cyclosporine was 201.6 mg, 96.8 mg, and 149.5 mg in kidney transplant patients, stem cell transplant patients, and heart transplant patients, respectively.

| Variable | Kidney transplantation | Stem cell transplantation | Heart transplantation |
|----------|------------------------|--------------------------|----------------------|
| Sex      |                        |                          |                      |
| Men      | 2058 (61.9)            | 474 (49.5)               | 839 (87.8)           |
| Women    | 1247 (37.5)            | 453 (47.3)               | 115 (12.0)           |
| Unknown  | 22 (0.7)               | 31 (3.2)                 | 2 (0.2)              |
| Age      |                        |                          |                      |
| Under 10 | 76 (2.3)               | 17 (1.8)                 | 155 (16.2)           |
| 10s      | 140 (4.2)              | 87 (9.1)                 | 237 (24.8)           |
| 20s      | 402 (12.1)             | 105 (11.0)               | 64 (6.7)             |
| 30s      | 615 (18.5)             | 114 (11.9)               | 23 (2.4)             |
| 40s      | 596 (17.9)             | 256 (26.7)               | 162 (16.9)           |
| 50s      | 733 (22.0)             | 318 (33.2)               | 229 (24.0)           |
| 60s      | 573 (17.2)             | 37 (3.9)                 | 81 (8.5)             |
| ≥70s     | 72 (2.2)               | 0 (0)                    | 0 (0)                |
| Unknown  | 120 (3.6)              | 24 (2.5)                 | 5 (0.5)              |
| Dose of cyclosporine, mg | 201.6 ± 139.9 | 96.8 ± 81.5 | 149.5 ± 93.0 |

**TABLE 2: Characteristics of the patients with adverse events associated with cyclosporine in the kidney, stem cell, and heart transplantation**

Values are expressed as number (%) or mean ± SD.
### TABLE 3: The top 10 adverse events associated with cyclosporine in kidney transplantation

*Signal detected. CI, confidence interval; PT, preferred terms; ROR, reporting odds ratio.

| PT                          | n   | ROR  | 95%CI         |
|-----------------------------|-----|------|---------------|
| Cytomegalovirus infection   | 358 | 1.37 | 1.21-1.55*    |
| Urinary tract infection     | 179 | 3.9  | 3.2-4.76*     |
| Nephropathy toxic           | 147 | 15.1 | 11-20.8*      |
| Pneumonia                   | 96  | 1.94 | 1.53-2.46*    |
| Diabetes mellitus           | 77  | 2.12 | 1.62-2.77*    |
| Hypertension                | 75  | 3.65 | 2.71-4.92*    |
| Blood creatinine increased  | 60  | 1.2  | 0.9-1.6       |
| Renal impairment            | 60  | 1.43 | 1.07-1.91*    |
| Escherichia urinary tract infection | 60  | 2.62 | 1.91-3.58*    |
| Pneumocystis jirovecii pneumonia | 58  | 1.61 | 1.19-2.17*    |

Table 4 shows the 10 most frequently reported adverse events by cyclosporine in stem cell transplantation. The most frequently reported adverse event was thrombotic microangiopathy (TMA) (51 reports), and its ROR was 3.83 (95% CI, 2.73-5.37). The signal score of adverse events caused by cyclosporine in stem cell transplantation for toxic nephropathy was highest (ROR, 216; 95% CI, 29.3-1593), followed by membranous glomerulonephritis (ROR, 190; 95% CI, 25.7-1412), and nephrotic syndrome (ROR, 95.2; 95% CI, 22.4-404).

### TABLE 4: The top 10 adverse events associated with cyclosporine in stem cell transplantation

*Signal detected. CI, confidence interval; PT, preferred terms; ROR, reporting odds ratio.

| PT                          | n   | ROR  | 95%CI         |
|-----------------------------|-----|------|---------------|
| Thrombotic microangiopathy  | 51  | 3.83 | 2.73-5.37*    |
| Renal disorder              | 47  | 10.5 | 6.78-16.1*    |
| Cytomegalovirus infection   | 27  | 2.64 | 1.7-4.1*      |
| Nephropathy toxic           | 26  | 216  | 29.3-1593*    |
| Nephrotic syndrome          | 23  | 95.2 | 22.4-404*     |
| Glomerulonephritis membranous | 23  | 190  | 25.7-1412*    |
| Liver disorder              | 22  | 1.21 | 0.77-1.91     |
| Neutropenia                 | 22  | 1.65 | 1.04-2.62*    |
| Pneumocystis jirovecii pneumonia | 21  | 17.3 | 8.13-36.9*    |
| Staphylococcal sepsis       | 21  | 1.84 | 1.14-2.97*    |

Unlike the adverse event profiles of cyclosporine in kidney and stem cell transplantation, the associations of cyclosporine with gastric cancer (ROR, 39.4; 95% CI, 16.7-95.2), pneumonia pneumococcal (ROR, 11.4; 95% CI, 6.24-20.9), and cholecystitis (ROR, 11.4; 95% CI, 6.24-20.9) were noteworthy in heart transplantation (Table 5).
**TABLE 5: The top 10 adverse events associated with cyclosporine in heart transplantation**

| PT                        | n  | ROR       | 95% CI       |
|---------------------------|----|-----------|--------------|
| Tonsillitis               | 90 | 8.48      | 6.11-11.8*   |
| Pharyngitis               | 48 | 2.28      | 1.62-3.21*   |
| Renal impairment          | 42 | 1.41      | 1.19*        |
| Gastric cancer            | 41 | 39.4      | 16.7-93.2*   |
| Pyrexia                   | 36 | 2.12      | 1.43-3.12*   |
| Cholelithiasis            | 32 | 10.7      | 5.94-19.4*   |
| Pneumonia pneumococcal    | 32 | 11.4      | 6.24-20.9*   |
| Cholecystitis             | 32 | 11.4      | 6.24-20.9*   |
| Blood creatine phosphokinase increase | 32 | 10.1      | 5.67-18.1*   |
| Cytomegalovirus infection | 31 | 4.63      | 2.67-7.48*   |

*Signal detected. CI, confidence interval; PT, preferred terms; ROR, reporting odds ratio.

**Discussion**

Using a large and nationwide study of pharmacovigilance data, we conducted a comparison of safety profiles by cyclosporine among kidney, stem cell, and heart transplant patients. In this study, renal and infectious adverse events were commonly detected in these transplant patients. Especially, cytomegalovirus infection was highly ranked and significantly correlated with cyclosporine in these transplant patients. On the other hand, there was variability in the safety profile of cyclosporine among these transplantations: cyclosporine in heart transplantation was significantly correlated with gastric cancer, but not in kidney or stem cell transplantation; however, cyclosporine in kidney transplantation was significantly correlated with toxic nephropathy, and cyclosporine in stem cell transplantation was significantly correlated with toxic nephropathy, nephrotic syndrome, and membranous glomerulonephritis. To the best of our knowledge, this is the first study to clarify the profiles of adverse events by cyclosporine in the kidney, stem cell, and heart transplant patients using a spontaneous reporting database.

Our pooled analysis of various types of transplantation showed that infectious adverse events were commonly reported: pneumonia pneumococcal and Cytomegalovirus infection in heart transplantation, Cytomegalovirus infection, urinary tract infection, Escherichia urinary tract infection, and Pneumocystis jirovecii pneumonia in kidney transplantation, and Cytomegalovirus infection, Pneumocystis jirovecii pneumonia, and staphylococcal sepsis in stem cell transplantation. Transplant patients by immunosuppressant use are at higher risk of infection compared with the general population. It has been reported that abnormalities in thymi and T-cell generation after cyclosporine administration are observed [13]. For example, cyclosporine causes involution of the thymic medulla [13], decreased single-positive thymocytes and peripheral T cells, and downregulated expression of class II MHC [14]. Then, abnormalities in thymi and T-cell generation in the presence of calcineurin inhibitors may provide an explanation for the increased risk of infection.

As for adverse events by cyclosporine in kidney transplantation, the signal score of cyclosporine was significantly higher for toxic nephropathy (ROR, 15.1; 95% CI, 11-20.8), urinary tract infection (ROR, 3.9; 95% CI, 3.2-4.76), and hypertension (ROR, 3.65; 95% CI, 2.71-4.92). Several studies have reported that cyclosporine was nephrotoxic in humans [15,16]. Patients treated chronically with cyclosporine showed that the decreases in glomerular filtration and renal perfusion were accompanied by a reduced proximal reabsorptive capacity [16]. In another study, activation of the vasoconstriction systems contributed to cyclosporine-induced nephrotoxicity [17]. In addition, cyclosporine elevated angiotensin II levels, angiotensin-converting enzyme activity, and angiotensin II type I receptor expression, which augments angiotensin-induced vasoconstriction [18,19]. The renal vasoconstriction can cause tissue hypoxia and enhance the formation of reactive oxygen species (ROS) that ultimately cause cellular injury and apoptosis. ROS plays an important role in cyclosporine-induced nephrotoxicity [20,21]. Cyclosporine-mediated induction of oxidative stress is associated with cyclophilin D, with cyclophilin D deletion providing a protective effect [22]. In our results, cyclosporine was significantly correlated with hypertension. It is consistent with a report that calcineurin inhibitor exposure is associated with irreversible changes in blood vessels (arterial hyalinosis) [18]. As another mechanism, underlying hypertension by cyclosporine, cyclosporine-mediated water, and sodium retention was demonstrated to contribute to the progression of...
As for adverse events by cyclosporine in heart transplantation, gastric cancer showed a positive association with cyclosporine in heart transplantation, and its signal score was noteworthy (ROR, 39.4; 95% CI, 16.7-95.2). Our results are consistent with the reports that the incidence of cancer is high in the transplant population [29-31]. Immunosuppressive drugs have been recognized as a major factor contributing to the increased incidence of cancer [29,30], especially virus-related cancers, in transplant recipients, suggesting that the increase is due to the loss of immune control of oncogenic viruses [29]. The incidence of malignancies might be related to the type of allograft; as reported previously, the highest incident rate of skin cancer was observed in heart transplant recipients and the lowest in liver transplant recipients [32]. This marked discrepancy in cancer frequency is partly due to the more intense immunosuppression used for the prevention of allograft rejection in organs. Cyclosporine treatment regimens in Japan are 9-12 mg/kg per day, 6-12 mg/kg per day, and 10-15 mg/kg per day in the kidney, stem cell, and heart transplant patients, respectively. Our results showed that doses of cyclosporine were highest for kidney transplant patients, followed by heart transplant patients and stem cell transplant patients. However, their age distributions were different; teenagers are most common among heart transplant patients, unlike kidney and heart transplant patients. Generally, teenage body weights are lower than in middle and old age, leading to lower doses in heart transplant patients than in kidney transplant patients. Then, the development of gastric cancer when cyclosporine was used for heart transplantation could be partly due to the cyclosporine treatment protocol after heart transplantation. In this study, the use of cyclosporine in heart transplantation showed a positive signal with gastric cancer, which will provide important information in clinical settings.

This pharmacovigilance study using the JADER database has several limitations. First, as in all pharmacovigilance studies, we were unable to calculate the true incidence rates, because of a lack of the total number of patients receiving the drugs of interest and underreporting. Especially, adverse events that are well-known by certain drugs are less likely to be reported. Second, in spontaneous reporting systems such as JADER, control populations are not included, so ROR is different from the “odds ratio” which is often used in epidemiological studies. In real terms, ROR denotes an increased likelihood of reporting an adverse event and not the risk of an adverse event per se. Third, the extent of actual exposure in the treated population is not available from the database. Finally, there might be other confounding factors associated with the adverse events, but the present method did not provide us with detailed clinical information on the patients.

**Conclusions**

This is the first study to reveal that there is diversity in the strength of association between cyclosporine and adverse events in kidney, stem cell, and heart transplantation in a real-world setting. This diversity is partly due to the age of the patients who develop the complication after immunosuppression and the cyclosporine treatment protocol for the patients after these transplantations. Physicians should be alerted in order to take precautions against the associated adverse events, and so potentially avoid them.

**Additional Information**

**Disclosures**

**Human subjects:** All authors have confirmed that this study did not involve human participants or tissue.

**Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue.

**Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following:

- **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work.

- **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

- **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
References

1. Lukas JC, Suárez AM, Valverde MP, et al.: Time-dependent pharmacokinetics of cyclosporine (Neoral) in de novo renal transplant patients. J Clin Pharm Ther. 2005, 30:549–57. 10.1111/j.1365-2710.2005.00683.x

2. Brigham MD, Milgrom A, Lencó MO, et al.: Immunosuppressant use and gut in the prevalent solid organ transplantation population. Proc Transplant. 2020, 30:103–10. 10.1111/transproceed.2020.01577

3. Grijó JM, Cruzado JM: Cyclosporine nephrotoxicity. Transplant Proc. 2004, 36:2405–25. 10.1016/j.transproceed.2004.01.057

4. Bechtel WO: Neurotoxicity of calcineurin inhibitors: Impact and clinical management. Transpl Int. 2000, 13:315–26. 10.1007/s001340050128

5. Mahé J, de Campaingo EP, Chené AL, Montastration JL, Despas F, Jollet P: Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigilBase. Br J Clin Pharmacol. 2018, 84:2375-85. 10.1111/bcp.13693

6. Lee Y, Choi A, Noh Y, Jeon HL, Choe SA, Shin YI: Signal detection of drospirenone-containing oral contraceptives: a disproportionality analysis using the Korea Adverse Event Reporting System Database, 2008-2017. BMJ Open. 2021, 11:e045948. 10.1136/bmjopen-2020-045948

7. Hosohata K, Inada A, Oyama S, Furusho D, Yamada H, Iwanaga K: Surveillance of drugs that most frequently induce acute kidney injury: a pharmacovigilance approach. J Clin Pharm Ther. 2019, 44:49–55. 10.1111/jcpt.12748

8. Inada A, Oyama S, Niinomi I, Wakabayashi T, Iwanaga K, Hosohata K: Association of Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs in pediatric patients: subgroup analysis based on a Japanese spontaneous database. J Clin Pharm Ther. 2019, 44:775–9. 10.1111/jcpt.13001

9. Kambara H, Hosohata K, Nakatsuji T, et al.: Safety profile of vonoprazan compared with proton pump inhibitors: Insight from a pharmacovigilance study. Pharmacoevid. 2020, 75:527–30. 10.1691/ph.2020.06064

10. Hosohata K, Oyama S, Niinomi I, Wakabayashi T, Inada A, Iwanaga K: Comparison of safety profiles of new oral anticoagulants with warfarin using the Japanese spontaneous reporting database. Clin Drug Investig. 2019, 39:565–70. 10.1007/s40261-019-00788-3

11. Niinomi I, Hosohata K, Oyama S, Inada A, Wakabayashi T, Iwanaga K: Pharmacovigilance assessment of drug-induced acute pancreatitis using a spontaneous reporting database. Int J Toxicol. 2019, 38:487–92. 10.1111/1093-6557.12990

12. Maignen F, Hauben M, Heng E, Van Holle L, Dogne JM: Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases. Drugcapecinodiopme 2014, 25:195–207. 10.1002/pds.3529

13. Sawanobori Y, Kitazawa Y, Ueda H, Matsuno K, Tokuda N: Cyclosporine nephrotoxicity and arterial hypertension: possible impact of the modulation of renin-angiotensin system of cyclosporine-evoked hypertension in rats: role of arterial baroreflexes and vasoreactivity. Physiol Res. 2017, 66:167–80. 10.18799/physiolres.95353

14. Naissant SA, Sabra R, Elmallah AI, El-Din MM, Khedr MM, El-Mas MM: Nephrotoxicity and arterial hypertension by 27-hydroxycholesterol. Drug Saf. 2014, 23:195–207.

15. Heering P, Schadewaldt P, Bach D, Grabensee B: Cyclosporin A inhibits differentiation and activation of monocytic cells induced cyclosporine A with a decrease of mature thymic epithelia, XCR1+ dendritic cells, and epithelium-free areas containing Foxp3+ thymic regulatory T cells. Histochem Cell Biol. 2021, 156:133–46. 10.1007/s00418-021-01993-y

16. Son Y, Choi J, Kim B, et al.: Cyclosporin A inhibits differentiation and activation of monocytic cells induced by 27-hydroxycholesterol. Int Immunopharmacol. 2019, 69:558–67. 10.1016/j.intimp.2019.01.045

17. Heering P, Schadewaldt P, Bach D, Grabensee B: Nephrotoxicity of cyclosporine in humans: effect of cyclosporine on glomerular filtration and proximal tubular reabsorption. Clin Investig. 1995, 71:1010–5. 10.1007/BF00180035

18. Karimzadeh I, Jafari M, Davani-Davari D, Ramzi M: Assessment of disproportionality analyses on two spontaneous reporting systems databases. Drugcapecinodiopme 2014, 25:195–207. 10.1002/pds.3529

19. Essefi I, Mâleik I, Kopkan L, Kautzner J: Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension. Physiol Res. 2017, 66:167–80. 10.33549/physiolres.95353

20. Nasser SA, Sabra R, Elmallah AI, El-Din MM, Khedr MM, El-Mas MM: Facilitation by the renin-angiotensin system of cyclosporine-evoked hypertension in rats: role of arterial baroreflexes and vasoreactivity. Life Sci. 2016, 163:1-10. 10.1016/j.lfs.2016.08.024

21. Kepkpin S, Karaca E, Yahamglou S, et al.: Resveratrol ameliorates the cyclosporine-induced vascular and renal impairments: possible impact of the modulation of renin-angiotensin system. Can J Physiol Pharmacol. 2019, 97:1115-23. 10.1139/cjp-2018-0753

22. Moon D, Kim J: Cyclosporin A aggravates hydrogen peroxide-induced cell death in kidney proximal tubule epithelial cells. Anat Cell Biol. 2019, 52:312–13. 10.5115/acb.18.192

23. Wu Q, Wang X, Nopovimova E, Wang Y, Yang H, Kuca K: Mechanism of cyclosporine A nephrotoxicity: oxidative stress, autophagy, and signalings. Food Chem Toxicol. 2018, 118:889–907. 10.1016/j.fct.2018.06.054

24. Klawitter J, Klawitter J, Pennington A, et al.: Cyclophilin D knockout protects the mouse kidney against cyclosporin A-induced oxidative stress. Am J Physiol Renal Physiol. 2019, 317:F683–94. 10.1152/ajprenal.00417.2018

25. Masl S, Ulliana M, Gesi M, Taddei S, Virdis A: Drug-induced hypertension: the problem to know how to deal with it. Vascul Pharmacol. 2019, 115:84–8. 10.1016/j.vph.2019.02.002

26. Gutigab V, Vatthik JW, Zheng J, et al.: Incidence and risk factors for acute and chronic kidney injury after adult cord blood transplantation. Biol Blood Marrow Transplant. 2020, 26:758–65. 10.1016/j.bbtm.2019.12.768

27. Yessayan L, Shafiq A, Peterison E, Wills K, Hsue H, Yu Y, Williams LJ, Lameur D: Race, calcineurin inhibitor exposure, and renal function after solid organ transplantation. Transplant Proc. 2015, 47:2968–72. 10.1016/j.transproceed.2015.10.052

28. Parikh CR, McSweeney PA, Kolaral D, et al.: Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int. 2002, 62:566–73. 10.1046/j.1523-1755.2002.00455.x

29. Mozó B, Horváth O, Sinkovits G, Vezséni X, Krisán G, Prohászka Z: Validation of early increase in complement activation marker sC5b-9 as a predictive biomarker for the development of thrombotic microangiopathy after stem cell transplantation. Front Med (Lausanne). 2020, 7:569291.
28. Elfeky R, Lucchini G, Lum SH, et al.: New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT. Blood Adv. 2020, 4:2418-29. 10.1182/bloodadvances.2019001315
29. Ergels EA, Pfeiffer RM, Fraumeni JF Jr, et al.: Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011, 306:1891-901. 10.1001/jama.2011.1392
30. Turshudzhyan A: Post-renal transplant malignancies: opportunities for prevention and early screening. Cancer Treat Res Commun. 2021, 26:100283. 10.1016/j.ctarc.2020.100283
31. Gibson JA, Cordaro A, Dobbs TD; et al.: The association between immunosuppression and skin cancer in solid organ transplant recipients: a control-matched cohort study of 2,852 patients. Eur J Dermatol. 2021, 31:712-21. 10.1664/ejd.2021-4108
32. Garrett GI, Blanc PD, Boscardin J, et al.: Incidence of and risk factors for skin cancer in organ transplant recipients in the United States. JAMA Dermatol. 2017, 153:296-305. 10.1001/jamadermatol.2016.4920